Menu Search
Equities

Ayala Pharmaceuticals Inc

FAD:MUN

Ayala Pharmaceuticals Inc

Actions
  • Price (EUR)0.455
  • Today's Change-0.025 / -5.21%
  • Shares traded1.00
  • 1 Year change-48.30%
  • Beta--
Data delayed at least 15 minutes, as of May 10 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company primarily focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. The Company's lead candidate is aspacytarabine (BST-236), a novel anti-metabolite for first line treatment in unfit acute myeloid leukemia (AML). Aspacytarabine (BST-236) is composed of cytarabine covalently bound to asparagine, acting as a pro-drug of cytarabine. It is also focused on the development and commercialization of proprietary Listeria monocytogenes (Lm)-based antigen delivery products. These efforts are primarily focused on the development of ADXS-504, a Lm-based therapy for early-stage prostate cancer.

  • Revenue in USD (TTM)13.00k
  • Net income in USD-48.07m
  • Incorporated2002
  • Employees20.00
  • Location
    Ayala Pharmaceuticals Inc9 DEER PARK DRIVE, SUITE K-1MONMOUTH JUNCTION 08852United StatesUSA
  • Phone+1 (732) 545-1590
  • Fax+1 (302) 674-5266
  • Websitehttps://ayalapharma.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.